Lausanne, Switzerland  – October 31, 2018 – Galderma, Nestlé Skin Health’s medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

• Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms¹
• Studies investigating the efficacy of Sculptra on areas beyond the face show patient

• Health, hygiene and safety of hands are more essential than ever
• CETAPHIL contributes to the challenge communities face from shortages of alcohol-based hand gels, by producing hand gels and donating skincare products to support caregivers, and promoting effective hygiene practices

Lausanne, Switzerland, May 1, 2020 - One of the m

– Galderma reaffirms its dedication to continued Sculptra innovation and scientific advancement, exploring Sculptra’s regenerative properties and potential use in non-facial treatment areas –

Leading Acne-Fighting Brand Continues to Address Consumers’ Needs with Complete Regimen of Innovative Skincare Solutions